Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,657
  • Shares Outstanding, K 15,112
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,650 K
  • 60-Month Beta 2.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.62
Trade ARTL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.87
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/12/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5855 +59.71%
on 12/21/20
1.2400 -24.59%
on 01/08/21
+0.3296 (+54.43%)
since 12/18/20
3-Month
0.4510 +107.34%
on 11/02/20
1.2400 -24.59%
on 01/08/21
+0.3081 (+49.14%)
since 10/19/20
52-Week
0.4510 +107.34%
on 11/02/20
4.4200 -78.84%
on 02/03/20
-1.4144 (-60.20%)
since 01/17/20

Most Recent Stories

More News
Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update

Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK

ARTL : 0.9351 (-3.59%)
Artelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference

ArteloBiosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C....

ARTL : 0.9351 (-3.59%)
Artelo Biosciences Files Patent Application for New Formulation of ART27.13

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid...

ARTL : 0.9351 (-3.59%)
Artelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid...

ARTL : 0.9351 (-3.59%)
S&P Leads Off December with Two Days of Record Highs

S&P Leads Off December with Two Days of Record Highs

EDIT : 72.11 (-5.29%)
BIGC : 62.36 (-0.02%)
SHOP : 1,173.97 (+0.30%)
INSG : 17.44 (+23.51%)
ARTL : 0.9351 (-3.59%)
ACB : 11.84 (-1.66%)
APHA : 13.61 (+9.58%)
CMBM : 29.36 (+2.66%)
Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid...

ARTL : 0.9351 (-3.59%)
Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid...

ARTL : 0.9351 (-3.59%)
Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss

First patients on track for enrollment this year

ARTL : 0.9351 (-3.59%)
Artelo Biosciences to Present at the Virtual Fall Investor Summit on November 18th

LA JOLLA, CA / ACCESSWIRE / November 11, 2020 / (NASDAQ:ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid...

ARTL : 0.9351 (-3.59%)
Great Start to November with Epic Election Week Rally

Great Start to November with Epic Election Week Rally

SFM : 21.19 (+1.29%)
INOV : 26.02 (-1.36%)
SNBR : 96.13 (+1.24%)
PRPL : 34.68 (-2.25%)
CATM : 40.40 (-0.76%)
ACB : 11.84 (-1.66%)
ARTL : 0.9351 (-3.59%)
GRWG : 52.31 (+2.35%)
NTR : 53.47 (-0.32%)
TOL : 46.12 (+3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company's product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc....

See More

Key Turning Points

3rd Resistance Point 1.0540
2nd Resistance Point 1.0164
1st Resistance Point 0.9758
Last Price 0.9351
1st Support Level 0.8976
2nd Support Level 0.8600
3rd Support Level 0.8194

See More

52-Week High 4.4200
Fibonacci 61.8% 2.9038
Fibonacci 50% 2.4355
Fibonacci 38.2% 1.9672
Last Price 0.9351
52-Week Low 0.4510

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar